Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection
06 juil. 2021 07h00 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa. and OXFORD, United Kingdom, July 06, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) and Vaccitech plc (Nasdaq: VACC) today announced that the companies have...
Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection
29 juin 2021 07h00 HE
|
Arbutus Biopharma Corporation
MENDHAM, N.J. and WARMINSTER, Pa., June 29, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the companies have entered into a...
Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress™ 2021 - All Selected for Best of ILC™
26 juin 2021 07h15 HE
|
Arbutus Biopharma Corporation
AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks AB-729 resulted in HBsAg declines below 100 IU/ml in 75%...
Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June
02 juin 2021 07h30 HE
|
Arbutus Biopharma Corporation
Conference Call and Webcast to discuss the new data being presented at EASL scheduled for 8:00 AM ET, Monday, June 28, 2021 WARMINSTER, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma...
Arbutus to Participate in Upcoming Investor Conferences
26 mai 2021 08h00 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with...
Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update
05 mai 2021 07h30 HE
|
Arbutus Biopharma Corporation
AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B...
Arbutus to Report First Quarter 2021 Financial Results and Provide Corporate Update
28 avr. 2021 08h00 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with...
Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement
01 avr. 2021 07h30 HE
|
Arbutus Biopharma Corporation
Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of COVID-19 and potential future coronavirus outbreaks ...
Arbutus Receives Regulatory Approval to Initiate a Phase 1a/1b Clinical Trial with AB-836, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Infection
16 mars 2021 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., March 16, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with...
Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update
04 mars 2021 07h30 HE
|
Arbutus Biopharma Corporation
AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, demonstrates robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with...